FOSUN PHARMA (02196) announced that its controlled subsidiary, Gismee (Wuhan) Pharmaceutical Co., Ltd., recently had the drug registration application for Cyclophosphamide Injection accepted by the National Medical Products Administration. The drug is a chemically synthesized pharmaceutical developed by the Group and is intended for the treatment of adult and pediatric patients with conditions including malignant lymphoma, Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt lymphoma, multiple myeloma, leukemia, mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast cancer. As of December 2025, the Group's cumulative R&D investment in this drug amounts to approximately RMB 7.4 million (unaudited).